GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Akorn, Inc. (AKRX) [hlAlert]

Rating:
Outperform
AKRX
up 0.43 %

Akorn, Inc. (AKRX) rated Outperform with price target $50 by William Blair

Posted on: Tuesday,  Dec 9, 2014  11:25 AM ET by William Blair

William Blair rated Outperform Akorn, Inc. (NASDAQ: AKRX) on 12/09/2014, when the stock price was $41.03. Since
then, Akorn, Inc. has gained 0.44% as of 01/22/2016's recent price of $41.21.
If you would have followed this William Blair's recommendation on AKRX, you would have gained 0.43% of your investment in 409 days.

Akorn, Inc. is engaged in manufacturing and marketing diagnostic and therapeutic pharmaceuticals in specialty areas, such as ophthalmology, rheumatology, anesthesia and antidotes, among others. In addition, the Company markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations and other pharmaceutical companies. It has a wholly owned subsidiary named Akorn (New Jersey), Inc., which operates in Somerset, New Jersey and is involved in manufacturing, product development, and administrative activities related to its ophthalmic and hospital drugs & injectables segments. The Company operates in four segments: ophthalmic, hospital drugs & injectables, biologics & vaccines and contract services.

The Equity Research department provides the firm's clients with in-depth investment analysis and investment recommendations. Acting as the company's laboratory for new investment ideas, it specializes in providing investment analysis on quality growth companies. Located together in our Chicago office, our equity analysts currently follow a universe of nearly 360 companies.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/9/2014 11:25 AM Buy
None
41.03 50.00
as of 8/27/2015
1 Week down  -4.31 %
1 Month down  -10.80 %
3 Months down  -0.88 %
1 YTD up  0.43 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy